Compugen Ltd.
Compugen Ltd. (CGEN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CGEN · as of Jun 8, 2026
Key Statistics
Explore Compugen Ltd. Data
cgen stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 92.9%
The CGEN analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $4.50, representing +120.59% upside from the current price of $2.04.
Competitors & Peers
cgen competitorsCGEN
CRBP
CRDF
CYBN
IPHA
MISTStock Performance
Full HistoryAbout Compugen Ltd.
Compugen Ltd. an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and p…
what is compugen ltd. · cgen stock overview · compugen ltd. company profile · who is compugen ltd. ceo · cgen NASDAQ · compugen ltd. headquarters · compugen ltd. business segments
About Stock Overview & Key Data
Compugen Ltd. (CGEN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 11, 2000. As of the latest trading session, CGEN stock price is $2.04, with a market capitalization of $192.9M. The stock has returned +20.00% over the past 12 months and +33.33% year-to-date.
According to 14 Wall Street analysts, the consensus rating for Compugen Ltd. stock is Buy, with an average 12-month price target of $4.50. In fiscal year 2025, Compugen Ltd. reported revenue of $72.8M and net income of $35.3M. For detailed data — including Compugen Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Compugen Ltd. (CGEN) stock price is $2.04. The stock is traded on NASDAQ under the ticker symbol CGEN. The 52-week range is $1.30 – $3.24.